Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HPVST cells |
Synonyms | |
Therapy Description |
HPVST cells are autologous T cells that are stimulated with HPV-16/18-loaded dendritic cells and are also engineered to express a dominant-negative TGF-beta receptor II that inhibits TGF-beta signaling, which potentially results in increased T cell response against HPV-16/18-positive tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HPVST cells | Autologous HPV-16/18 E6/E7-specific TGF-beta-resistant T Lymphocytes | HPVST cells are autologous T cells that are stimulated with HPV-16/18-loaded dendritic cells and are also engineered to express a dominant-negative TGF-beta receptor II that inhibits TGF-beta signaling, which potentially results in increased T cell response against HPV-16/18-positive tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02379520 | Phase I | Cyclophosphamide + Fludarabine + HPVST cells + Nivolumab HPVST cells | HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA) | Active, not recruiting | USA | 0 |